Merck KGaA’s BTK inhibitor had been hailed as the first to show activity in multiple sclerosis, but full clinical results cast doubt on this claim.
cMet emerges as the latest genetic mutation that could soon see targeted treatments become available.
Approvals for new uses of old drugs should far outweigh nods for novel projects in June.
Peloton Therapeutics’ approach to fighting kidney tumours has apparently convinced Merck & Co, which is to pay $1.05bn for the company on the back of relatively…
The group follows licensing deals with Dainippon and Roivant with a pivotal study win.
As the plot thickens around the trigger for Aveo’s equity raise, the EU regulator considers pulling the group's renal cancer drug from the market.
After two checkpoint combo trials flopped last month Syndax celebrates an unexpected win in a third.
A patient death notwithstanding, Chi-Med reckons results from the Tatton study justify its US registration strategy.